Male contraception
Copyright © 2023. Published by Elsevier Masson SAS..
CONTEXT: Contraception is a major global health issue, which is still dominated by female contraception. Developments in male contraception could help redistribute the contraceptive burden.
METHODS: A literature search was carried out to review the existing options and the criteria for optimal contraception, to establish the principles of a male pre-contraception consultation, and to review the various research avenues with their advantages and disadvantages.
RESULTS: The new male contraception options are detailed, whether hormonal (androgen therapy, combination of progestins and testosterone) or non-hormonal, particularly thermal, with current results and avenues for improvement. Condom use and vasectomy remain the only 2 validated options. The recent development of minimally invasive vasectomy without the need for a scalpel and of occlusion techniques has simplified the procedure, minimised the risk of complications (pain, haematomas, post-vasectomy pain syndrome) and improved efficacy. The issues of regret and the possibility of repermeabilisation are also raised.
CONCLUSION: The question of male contraception will become increasingly important in consultations with urologists. The urologist will have to inform the patient, as required by law, before the vasectomy is performed, and provide the best possible advice on the technique, which will often be minimally invasive without the need for a scalpel. New reversible options should also broaden the range of options available on a routine basis, with a view to gradually moving towards contraceptive equity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie - 33(2023), 13 vom: 17. Nov., Seite 718-732 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Contraception masculine |
|---|
| Beteiligte Personen: |
Faix, A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.11.2023 Date Revised 29.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.purol.2023.09.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365040967 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365040967 | ||
| 003 | DE-627 | ||
| 005 | 20231226100830.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.purol.2023.09.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1216.xml |
| 035 | |a (DE-627)NLM365040967 | ||
| 035 | |a (NLM)38012914 | ||
| 035 | |a (PII)S1166-7087(23)00206-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Faix, A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Male contraception |
| 246 | 3 | 3 | |a Contraception masculine |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.11.2023 | ||
| 500 | |a Date Revised 29.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier Masson SAS. | ||
| 520 | |a CONTEXT: Contraception is a major global health issue, which is still dominated by female contraception. Developments in male contraception could help redistribute the contraceptive burden | ||
| 520 | |a METHODS: A literature search was carried out to review the existing options and the criteria for optimal contraception, to establish the principles of a male pre-contraception consultation, and to review the various research avenues with their advantages and disadvantages | ||
| 520 | |a RESULTS: The new male contraception options are detailed, whether hormonal (androgen therapy, combination of progestins and testosterone) or non-hormonal, particularly thermal, with current results and avenues for improvement. Condom use and vasectomy remain the only 2 validated options. The recent development of minimally invasive vasectomy without the need for a scalpel and of occlusion techniques has simplified the procedure, minimised the risk of complications (pain, haematomas, post-vasectomy pain syndrome) and improved efficacy. The issues of regret and the possibility of repermeabilisation are also raised | ||
| 520 | |a CONCLUSION: The question of male contraception will become increasingly important in consultations with urologists. The urologist will have to inform the patient, as required by law, before the vasectomy is performed, and provide the best possible advice on the technique, which will often be minimally invasive without the need for a scalpel. New reversible options should also broaden the range of options available on a routine basis, with a view to gradually moving towards contraceptive equity | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Condom | |
| 650 | 4 | |a Contraception | |
| 650 | 4 | |a Contraception hormonale | |
| 650 | 4 | |a Contraception thermique | |
| 650 | 4 | |a Hormonal contraception | |
| 650 | 4 | |a Indice de Pearl | |
| 650 | 4 | |a Non-scalpel vasectomy | |
| 650 | 4 | |a Pearl index | |
| 650 | 4 | |a Préservatif | |
| 650 | 4 | |a Thermal contraception | |
| 650 | 4 | |a Vasectomie sans scalpel | |
| 650 | 7 | |a Contraceptive Agents, Male |2 NLM | |
| 650 | 7 | |a Contraceptive Agents |2 NLM | |
| 700 | 1 | |a Methorst, C |e verfasserin |4 aut | |
| 700 | 1 | |a Hupertan, V |e verfasserin |4 aut | |
| 700 | 1 | |a Huyghe, E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie |d 1997 |g 33(2023), 13 vom: 17. Nov., Seite 718-732 |w (DE-627)NLM012649481 |x 1166-7087 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2023 |g number:13 |g day:17 |g month:11 |g pages:718-732 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.purol.2023.09.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2023 |e 13 |b 17 |c 11 |h 718-732 | ||